Executive Director in BD&L, MSD/Merck
Khatereh Ahmadi has worked in the biotech/pharma industry for 15 years. Previous to her current role at MSD/Merck as Executive Director in BD&L in the oncology field, she was a co-founder and CEO of reViral Ltd, leading a Series A round of $21M with EdRIP and Orbimed. She played a significant role in the spin out of Piramed Ltd, and subsequently became head of business development culminating in a significant deal with Genentech and acquisition of Piramed by Roche in 2008. She has consulted for a number of EU and US companies in the oncology field. She obtained a PhD in biochemistry from King’s College London and held a post-doctoral position at the Ludwig Institute for Cancer Research in London working in the PI 3-kinase field. Dr. Ahmadi was awarded her MBA from Henley Management College.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557